MOTS-c
Mitochondrial-derived peptide
Checked Oct 28, 2026
GROUND TRUTH PEPTIDES · PEPTIDE FACTS
MOTS-c
Evidence grade for: Metabolic health, endurance and longevity in healthy or prediabetic adults
No human evidence yet
- AProven
- BHuman trial
- CEarly data
- DNo human data
CLAIMED, NOT PROVEN
People take it hoping for better blood sugar control, more endurance and slower aging; it is a 16-amino-acid peptide made from mitochondrial DNA.
WHAT HAS BEEN SHOWN
Grade D, animal only: it improved running capacity and insulin handling in mice, and no human trial of injected MOTS-c has reported results, so whether it works in people is unknown.
FDA STATUS
Not FDA approved. FDA staff recommended against a compounding listing in July 2026. An HHS draft policy (Oct 30, 2026) concerns compounding only.
RISK
No human safety data for injected MOTS-c exists, and FDA says it cannot rule out immune reactions and aggregation with injection.
DOSE
Not on this card. See the full page.
PLACEBO
No controlled human trial of injected MOTS-c exists for any use, so a placebo effect cannot be ruled out for anything a user feels.
Information, not medical advice. Talk to a licensed clinician before you act on it. Checked 2026-10-28. groundtruthpeptides.com
We tried it. This is what happened.
- MOTS-c: the one my body voted against StoppedThree starts, three stops. The last one ended after a second reaction, and that is the end of the experiment.
The full answer: what it is for, the dose, the units
What people take it for: People take it hoping for better blood sugar control, more endurance and slower aging; it is a 16-amino-acid peptide made from mitochondrial DNA.
Does it work for metabolic health, endurance and longevity in healthy or prediabetic adults? D, no human evidence yet. Result: not tested in humans.
Grade D, animal only: it improved running capacity and insulin handling in mice, and no human trial of injected MOTS-c has reported results, so whether it works in people is unknown.
No approval for any use.
Safety: D, uncharacterized. No human safety data for injected MOTS-c exists, and FDA says it cannot rule out immune reactions and aggregation with injection.
Do not use if: Undefined, there is no human safety dataset to derive them from.
Could it be placebo? No controlled human trial of injected MOTS-c exists for any use, so a placebo effect cannot be ruled out for anything a user feels.
The dose people use, and the units to draw
No verified dose statement found: no label, published human trial, Huberman Lab or Dr. Abud Bakri episode, Examine page or Attia episode gives a human dose, and the FDA review says dose-response is missing.
| Source | Dose | How often and how | Who it was for | Link |
|---|---|---|---|---|
| ClinicalTrials.gov NCT07505745 (MOTS-MET), Phase 2a, Hudson Biotech | No amount stated in the registry record | Subcutaneous injection, fixed dose once daily for 12 weeks, randomized 1:1 to MOTS-c or placebo | 120 adults with prediabetes and overweight or obesity; recruiting, no results | Arms and Interventions: Regimen |
| FDA briefing document, MOTS-c, July 23 2026 PCAC | No human dose stated | The nominator proposed 5 mg and 10 mg lyophilized vials for subcutaneous injection (a product strength, not a dosing statement) | Compounding nomination, no human population | Nomination summary (vial strengths); Human Safety section; Effectiveness conclusion |
| USADA, What is the MOTS-c peptide? | No dose stated | Not applicable | Athletes (anti-doping education page) | Page text |
No verified dose statement found. Checked: FDA briefing document (no human dose), ClinicalTrials.gov NCT07505745 (once daily for 12 weeks, amount not published), USADA (none), PubMed (no published trial of injected MOTS-c; the five trials that mention it measure the body's own MOTS-c levels after exercise, metformin or heat), Examine (no page found), Huberman Lab, Dr. Abud Bakri and Peter Attia (no MOTS-c episode found). Dose ranges printed on this site before had no named non-seller source and are removed.
Reported by the named source, never prescribed by us.
How many units do I draw?
Use the calculator: concentration is vial mg divided by water mL, and a U-100 insulin syringe holds 100 units per mL. Open the dose calculator
Why it might work
- MOTS-cfrom mtDNA
- Activates AMPKmetabolic switch
- Antioxidant genes
- Exercise-mimeticassumed
Assumed pathway, not shown in people.
Assumed, with striking animal support: MOTS-c is a peptide encoded inside mitochondrial DNA that activates AMPK, a master metabolic switch, and antioxidant gene programs, behaving like an exercise mimetic. The first human trial only began in 2026.
The trials, claim by claim
Every MOTS-c claim is animal-only or mechanistic, so the result tag reads 'not tested in humans'. The one registered human trial has not reported.
Exercise mimetic / boosts endurance.
Result: not tested in humans
In aged (22-month) mice, MOTS-c markedly improved running/endurance capacity. No human performance data exists.
Reynolds et al., Nat Commun 2021, aged-mouse enduranceImproves insulin sensitivity.
Result: not tested in humans
Strong animal and mechanistic data on glucose metabolism; the first human trial testing exactly this began in 2026 with no results yet.
NCT07505745, Phase 2a MOTS-c in prediabetes. ClinicalTrials.govSlows cellular aging.
Result: not tested in humans
A 2025 mechanistic paper reported MOTS-c prevents pancreatic islet-cell senescence in a model. This is a laboratory mechanism, not a human outcome.
Kong et al., Exp Mol Med 2025, islet-cell senescenceNo published case report or study documents hypersensitivity, flushing or histamine-type reactions with MOTS-c; online reports of immune-type reactions and fever are unconfirmed.
Result: not tested in humans
Absence of controlled data. FDA's adverse-event database had zero MOTS-c reports through March 2025, and FDA says it cannot conclude immunogenicity and aggregation risks with subcutaneous injection are absent. USADA lists user-reported reactions as anecdotes.
FDA briefing document, MOTS-c, July 2026 PCACMOTS-c is a cationic, amphipathic peptide with antibacterial and immune-modulating activity in mice and mouse cells.
Result: not tested in humans
Mouse peritonitis model and mouse monocyte differentiation. No human data.
Rice et al., eLife 2026, MOTS-c as a host defense peptideRisks and the label warnings
Adverse events
Unknown. FDA's July 2026 review found no human safety data and no adverse-event reports, and said it is concerned about immune reactions to an injected peptide. People who buy it online report palpitations, injection-site irritation, insomnia, fever and immune-type reactions. These are anecdotes: no case report or study has confirmed or explained them.
Contraindications
Undefined, there is no human safety dataset to derive them from.
Theoretical concerns
As a naturally occurring signaling peptide, the theoretical profile is reassuring, but 'endogenous' does not mean 'safe at injected doses.'
What nobody knows yet
Effective dose, route, durability, how long it lasts in blood (FDA cites rapid breakdown in human blood in a lab study), immune reactions to the injected peptide, drug interactions, and essentially all human safety.
What else could explain the result
MOTS-c is popular with people already optimizing hard, training, GLP-1s, caloric control. Any metabolic improvement they report is hopelessly entangled with those much-better-evidenced variables.
Is the vial what it says?
Injected, so the full standard applies: HPLC ≥98%, mass-spec identity, LAL endotoxin, from an independent lab. Identity verification is especially important for an expensive peptide that is easy to under-fill or substitute.
Half-life and storage
Half-life: Not well characterized in humans. Its development was historically slowed by stability and delivery challenges.
Once mixed: Standard peptide fragility, refrigerate, don't shake. Stability has been a real formulation problem for this one, so handling care matters more than most.
What I noticed, and what people report
Case study
- MOTS-c: the one my body voted against StoppedThree starts, three stops. The last one ended after a second reaction, and that is the end of the experiment.
What people report
Volume of reports: faint. Little real-world record, or mostly noise.
Thin first-person corpus, most indexed MOTS-c content is vendor SEO and academic papers, not user logs.
Only one lived claim converges (endurance / work capacity); metabolic and fat-loss claims are sparse, mixed, and stack-confounded.
If you only read the blogs you'd massively overrate it; the real ledger (MESO-Rx, including 'doing absolutely nothing' threads) is small.
- Reported uses center on metabolic health, endurance, and fat loss, usually by people already optimizing hard.
- Reports are enthusiastic but sparse, and very hard to separate from training and diet.
- Few side-effect reports; the honest read is 'not enough people have used it carefully to know.'
Reports are anecdote, not proof.
Can you tell if it is working?
The two honest objective proxies are a 14-day CGM (glucose mean/variability) and lab VO2max/CPET, both map to MOTS-c's claimed metabolic and endurance effects, but both are confounded by diet/training and unproven in humans.
Bloodwork
Nothing on a routine panel confirms this one. Anyone who says otherwise is guessing.
MOTS-c is a 16-aa mitochondrial-derived peptide that acts intracellularly through AMPK as an "exercise mimetic"; its own level is measurable only by a research ELISA (not any routine panel), and it produces no efficacy footprint on standard labs that could be separated from diet, training, or weight.
Read this before you spend on labs
Routine bloodwork cannot confirm that MOTS-c is working. There are no completed human efficacy trials of exogenous MOTS-c, and endogenous MOTS-c is quantifiable only by a research ELISA, not any LabCorp/Quest offering. Mechanistically it is a metabolic/AMPK peptide, so the only place anyone would even look is fasting insulin, HbA1c, and fasting glucose (with HOMA-IR), but those markers are dominated by diet, training load, and body weight, and no human data ties an injected MOTS-c dose to a shift in any of them. Any metabolic-panel improvement seen while running MOTS-c cannot be attributed to the peptide over the lifestyle changes that typically accompany it. Treat metabolic labs as general health context, not as proof MOTS-c is doing anything.
Other ways to track it
14-day continuous glucose monitor (Dexcom Stelo / Abbott Lingo), mean glucose, time-in-range, glucose variability (SD/CV), post-meal excursions
A working metabolic effect would show a modest drop in mean glucose, tighter variability (lower CV), and flatter post-meal excursions versus a matched baseline. No proven human magnitude exists (the first human trial only began in 2026), and any change is easily confounded by diet, carbs, sleep, and training, so hold meals and routine constant across baseline vs on-cycle windows or the signal is meaningless.
MOTS-c activates AMPK and increases skeletal-muscle glucose uptake and fatty-acid oxidation, improving insulin sensitivity in animal models; if that translates to humans it should surface as lower ambient glucose and tighter excursions on CGM.
Lab CPET (graded treadmill/cycle with gas exchange) for a true VO2max, or a consumer wearable estimate (Garmin/Apple Watch/COROS) as a rough trend line only
If the exercise-mimetic effect is real in humans, aerobic capacity / time-to-exhaustion should trend upward. But VO2max responds powerfully to training itself, and wearable estimates are noisy run-to-run, so a small change cannot be pinned on the peptide without a lab CPET and a held-constant training block. No human efficacy data exists yet, this is the weaker of the two proxies because attribution is dominated by the training confound.
In aged mice MOTS-c markedly improved running/endurance capacity as an exercise mimetic; the human-relevant footprint of that claim is cardiorespiratory fitness (VO2max), not any routine blood marker.
Bottom line
MOTS-c's first human trial only began in 2026, so there is zero completed human efficacy data, everything here is animal-derived plausibility (AMPK/insulin-sensitivity from cell and rodent work, endurance from aged-mouse studies). CGM and VO2max are the right objective proxies because they map to those two animal findings, but both readouts are dominated by diet, sleep, and training, and VO2max is especially confounded because training alone moves it. A change you observe is far more likely to come from lifestyle than from the peptide, so standardize every variable, use a true baseline, and treat any signal as suggestive, not proof. There is no validated human blood biomarker of MOTS-c efficacy, so blood adds nothing beyond a noisier version of the CGM signal.
Logging baseline vs retest is the whole game. The Truth Tracker is our free log for bloodwork, DEXA, genetics, and wearable data, bring your own numbers.
How to track itHistory
First documented human use: No human results exist. The first registered human trial, a randomized, placebo-controlled Phase 2a study of insulin sensitivity in 120 adults with prediabetes (NCT07505745), began in February 2026 and has not reported.
Update: an FDA advisory panel voted in favor of this one on July 23-24, 2026
The FDA's Pharmacy Compounding Advisory Committee voted to recommend adding this to the 503A Bulks List, meaning compounding pharmacies could legally prepare it. The vote: 7-5, with two abstentions. Now read the fine print, because it matters more than the headline. The vote is advisory and changes nothing today: FDA still has to go through formal rulemaking, which can take a year, and it has overruled its own panels before. As of November 2, 2026, FDA has not published a proposed rule and this is not on the 503A Bulks List. Separately, HHS published a draft enforcement-discretion policy in the Federal Register on October 30 (docket HHS-OASH-2026-0496) that says HHS does not intend to act against pharmacies that compound certain single-ingredient peptides under conditions. The notice itself says compounded drugs are not FDA-approved. That is enforcement discretion: a draft, not a rule, not approval, and not a ruling that the compound works, and HHS can revise it. The list of named peptides and routes sits in an appendix we could not open, so which peptides it names is as press and law firms report it, not as we read it. FDA's own scientists recommended AGAINST adding it, citing thin human evidence and unassessed immunogenicity risk, and the committee voted the other way. That committee is also not neutral: it was reconstituted with recent appointees, and several work at or run clinics that sell peptide treatments. And none of this is a finding that the compound works. A compounding-eligibility vote is not drug approval, and it is not evidence. Our grade here is unchanged, because the evidence did not change.
Vote tallies as reported by the press (STAT, McDermott Will and Schulte); FDA has not posted tallies, minutes or a transcript, and its meeting materials are on its meeting page. Rechecked November 2, 2026 against FDA and Federal Register primary pages: FDA has published no proposed rule, docket FDA-2025-N-6895 closed July 22, 2026, and HHS published a draft enforcement-discretion policy in the Federal Register on October 30, 2026 (docket HHS-OASH-2026-0496). Nothing here is final, so check the current policy and rule before acting.. FDA, PCAC meeting, July 23-24 2026
- 2015MOTS-c identified as a peptide encoded within mitochondrial DNA.
- 2015-2025Animal and in-vitro work shows metabolic and endurance effects; development slowed by delivery and stability challenges.
- 2025Mechanistic paper links MOTS-c to delayed islet-cell senescence.
- Apr 2026First registered human trial (Phase 2a, placebo-controlled, prediabetes) posted, no results yet.
- Apr 22 2026Off FDA Category 2: FDA's page lists it as nominated but withdrawn by the nominators. Not a safety finding, not Category 1 and not an approval. PCAC review scheduled Jul 23 2026.
- Jul 23 2026PCAC voted 7-5 (2 abstentions) to recommend MOTS-c for addition to the 503A Bulks List. Advisory only: no FDA proposed rule as of Oct 12 2026, and no evidence grade moves on a compounding vote.
All sources
- Lee et al., Cell Metab 2015, MOTS-c promotes metabolic homeostasis (mice)
- NCT07505745, Phase 2a MOTS-c in prediabetes. ClinicalTrials.gov
- FDA briefing document for MOTS-c, July 23 2026 PCAC
- FDA, Pharmacy Compounding Advisory Committee briefing document, MOTS-c, July 23 2026. FDA states it did not identify clinical studies evaluating administration of MOTS-c to humans and that dose-response relationships for MOTS-c are missing.(dose table)
- ClinicalTrials.gov record NCT07505745, arms and interventions module, status verified March 2026.(dose table)
- U.S. Anti-Doping Agency, 'What is the MOTS-c peptide?' States there are no completed human clinical trials and that safe conditions of use are unknown.(dose table)
Not medical advice. Grades reflect the evidence as of the date above and will change as data arrives. Reports from users are anecdote, not proof. Talk to a licensed clinician before you act on anything here.